PSY16 Effect of the Anti-Tumor Necrosis Factor Adalimumab on Work Productivity in Patients With Chronic Immune-Mediated Inflammatory Diseases: Literature Review  by Granados, D. et al.
tis, 5 for psoriasis and 3 for Crohn’s disease. Available information for each condi-
tion is presented hereafter. In rheumatoid arthritis, absenteeism ranged from 25 to
56 days per year and presenteeism was estimated to 55 days. The mean cost of
absenteeism in this condition ranged from €709 to €10,166. In ankylosing spondy-
litis, annual absenteeism ranged from 6 to 65 days, which represented €726 to
€2,532 per patient. Presenteeism was estimated to 14 days loss with an associated
annual cost of €1,027. In psoriasis, annual absenteeism ranged from 3 to 14 days
and presenteeism from 16 to 35 days. The costs of work productivity loss (absen-
teeism  presenteeism) in psoriasis ranged from €1,675 to €6,300. In Crohn’s dis-
ease, annual absenteeism was of 120 days per patient in median, which repre-
sented a cost of €4,745. No data on presenteeism was found. CONCLUSIONS:
Chronic immune-mediated inflammatory diseases have a high impact on work
productivity loss due to both number of days at work lost and decreased perfor-
mance with substantial costs.
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OBJECTIVES: To assess the improvement in work productivity associated with
adalimumab therapy in chronic immune-mediated inflammatory diseases.
METHODS: A systematic and computerized search was performed in the literature
published in English from 2000 to 2011 in Pubmed. The search terms were: ‘crohn
disease’, ‘spondylitis, ankylosing’, ‘psoriasis’, ‘rheumatoid arthritis’, ‘work produc-
tivity’, ‘productivity’, ‘absenteeism’, ‘sick leave’, ‘employment status’ and ‘adali-
mumab’. Questionnaires used to measure the work productivity were identified.
Results were annualized and costs converted in Euros and actualized to 2010 using
exchange rates and price indexes provided by the Organisation for Economic Co-
operation and Development. RESULTS: Nine clinical trials and one meta-analysis
were analyzed: 5 in rheumatoid arthritis, 1 in ankylosing spondylitis, 3 in psoriasis
and 1 in Crohn’s disease. Work Productivity and Activity Impairment (WPAI) ques-
tionnaire was used in 62% of studies. In rheumatoid arthritis, adalimumab was
associated with a 8-to-21-working day per year decrease in absenteeism and an
8-to-10-day decrease in presenteeism. In ankylosing spondylitis, adalimumab was
associated with a decrease of 8 working days per year in absenteeism and a 50 day
decrease in presenteeism. In psoriasis, adalimumab was associated with a de-
crease of 27 days in presenteeism but no significant improvement of absenteeism
was observed in this condition. In patients with moderate to severe Crohn’s dis-
ease, treatment with adalimumab was associated with a 18 working day per year
decrease in absenteeism and a 47-day decrease in presenteeism. Costs saving re-
lated to increased global work productivity (absenteeism and presenteeism) were
estimated to €1,720 per patient per year in rheumatoid arthritis and €7,625 in
Crohn’s disease. CONCLUSIONS: Adalimumab provided clinically significant im-
provements in work productivity that could be associated with savings of to € 7,625
in improved work productivity in Crohn’s disease.
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OBJECTIVES: Immune thrombocytopenia (ITP) is an immunologic blood disorder
characterised by low platelet counts and bleeding. The management of ITP aimed
at minimising bleeding events. Eltrombopag is an oral thrombopoietin receptor
agonist indicated as second line treatment of chronic ITP in adults. This economic
study estimated the direct costs of ITP management with eltrombopag in the
French setting. METHODS: A phase III clinical trial (RAISE) compared the response
to once daily eltrombopag versus placebo in adult patients with chronic ITP during
a 6-month period. Use of medical resources was assessed from the RAISE data
regarding eltrombopag dosage, treatment duration, bleeding-related events (BREs
grade 2), rescue therapy (IVIG, oral steroids), concomitant medications and hos-
pitalisations. The economic analysis was restricted to direct costs (2011 values)
measured in the perspective of the French Sickness Fund (full coverage for ITP).
RESULTS: For 6 months of treatment, total cost per patient receiving eltrombopag
(mean dose: 55.2mg) was estimated at 15,318 € with 88.9 % of the costs induced by
the main drug treatment. Monitoring costs related to eltrombopag (blood tests and
visits) were estimated at 403 € (2.6%). At least, concomitant drugs, BREs and rescue
therapy were respectively accounting for 623 € (4.1%), 730 € (4.8%) and 344 € (2.2%).
These results seem consistent with other French economic estimations concerning
patients treated with IVIG (13,291 €/6 months) or patient treated with romiplostim
(3g/Kg, 17,486 €/6 months). CONCLUSIONS: With the data from the RAISE clinical
trial, the direct cost for a patient treated with eltrombopag during a 6 months
period was estimated at 15,318 €. Estimation of direct costs may be envisaged in an
exploratory manner when Phase III clinical trials are close to real practice manage-
ment and has to be confirmed by collected resource utilization in observational
studies.
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OBJECTIVES: Day-to-day clinical practice outcomes and related costs are impor-
tant not only to confirm clinical trial results but also to inform more efficiently
clinical decision making. The objective of this retrospective study was to charac-
terize the main treatment outcomes and associated costs of a MDS and AML pa-
tient’s population in a hematology center in Portugal. METHODS: Adult patients
(n27) with MDS or AML at diagnosis and eligible for treatment with azacitidine at
any stage of their disease were eligible. Retrospective data was obtained from
hospital clinical records. Treatment outcomes included time-to-leukemia (TTL),
leukemia-free survival (LFS) and overall survival (OS). Survival analysis was per-
formed with the standard non-parametric Kaplan-Meier method. Costs were esti-
mated by multiplying resource utilization frequencies by their unit prices.
RESULTS: Mean follow-up was 15 months (min-max: 2.1-31.2). Mean (SD) age at
diagnosis was 67 (11) years. Nine patients (33%) were in IPSS risk intermediate-1
while the reminder (67%) were IPSS intermediate-2 or high. Median TTL, LFS and OS
were 20.4 months (95% CI: 11.3-NR), 15.3 months (95% CI: 11.0-20.4) and 17.2
months (95% CI: 14.1-29.8) respectively. Mean overall hospital related treatment
costs were 55,470€ per patient (min-max: 2,302€- 130,264€), an average (SD) of
4,017€ (1,593€) per month. CONCLUSIONS: Treatment outcomes in this population
are in the range of those reported in azacitidine clinical trials and other observa-
tional studies. Up to date effective management of MDS/AML is associated with
costly health care.
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OBJECTIVES:Oral anticoagulation therapy (OAT) with a vitamin K antagonist (VKA)
requires frequent monitoring of blood clotting, which involves great amounts of
time and costs. Newer technologies offer patients the possibility to perform home
monitoring of OAT. The objective of this study was to assess the economic impact
of patient self-management (PSM) of OAT compared with standard clinic monitor-
ing in a Canadian context. METHODS: A cost-consequence analysis was per-
formed, according to the perspective of the Province of Quebec health care system
and the societal perspective. A time horizon of one year of OAT monitoring was
chosen. Clinical data was obtained from a randomized Montreal Heart Institute
clinical trial by Verret et al., which compared clinical efficacy and quality of life
(QoL) of PSM versus standard monitoring. From the health care system perspective,
costs considered were those associated with test strips, physician visits, pharma-
cist time and patient training. From the societal perspective, the additional costs
associated with the acquisition of the monitoring machine, and time dedicated to
monitoring were considered. RESULTS: Annual costs per patient of 372.53 CAD$
and 397.27 CAD$ were associated with standard monitoring and PSM respectively
under the health care system perspective. Annual costs per patient were estimated
at 1,116.08 CAD$ for standard monitoring while annual PSM costs were estimated
at 533.19 CAD$ under the societal perspective. Both OAT methods were shown to be
clinically equivalent, however a significant improvement of QoL was found in PSM.
CONCLUSIONS: From the health care system perspective, PSM is slightly more
expensive than standard monitoring of OAT (24,74 CAD$), but from the societal
perspective PSM is associated with significant savings compared to standard mon-
itoring of OAT (-582.89 CAD$). Also, PSM is associated with improves patient’s QoL
while assuring the same monitoring quality as standard monitoring of OAT.
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OBJECTIVES: To assess the cost-effectiveness of prophylaxis vs on-demand ther-
apy with Anti Inhibitor Complex Concentrate (AICC). METHODS: Hemophilia A
patients 2 years with inhibitors and using bypassing therapy to treat bleeding
were recruited in a prospective, randomized, crossover study comparing 6 months
of AICC prophylaxis therapy with 6 months of on-demand therapy. The prophy-
lactic and on demand periods were separated by a 3-month washout. Cost evalu-
ation was based on direct (clotting factors, hospitalization, outpatient care, physi-
cians’ visit and other pharmacological therapy) and indirect (days of school/work
missed because of bleeding) costs, adopting the perspective of the third party
payer. Costs are expressed in US$ of 2011. We calculated the incremental cost per
bleeding avoided and the cost-effectiveness acceptability-curve. RESULTS: Twen-
ty-six patients were enrolled. The per-patient six-months cost during prophylaxis
period was 496,393 US$ compared with 211,330 US$ on on-demand. The incremen-
tal cost-effectiveness ratio in the prophylaxis vs on demand period was 34,852 per
bleeding event avoided. The acceptability curve showed there would be a 93%
likelihood that prophylaxis therapy would be considered cost-effective at willing-
ness-to-pay threshold of US$ 50,000 per bleeding event avoided. In Subjects with a
50% reduction in bleeding events, the incremental cost-effectiveness ratio in the
prophylaxis vs on demand period was US$ 25,877 per bleeding event avoided. In
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